Which Country Is Padcev (Enfortumab Vedotin) Cheapest In? — 2026 Guide

Why does the price differ so much between countries?

Padcev (enfortumab vedotin) is a Nectin-4-directed antibody–drug conjugate delivering the microtubule poison MMAE directly into urothelial carcinoma cells, approved for locally advanced or metastatic bladder cancer and, increasingly, given together with pembrolizumab in earlier lines of treatment. It is supplied as a lyophilised powder in 20 mg or 30 mg single-use vials that a hospital pharmacist must reconstitute and further dilute before intravenous infusion — there is no oral or self-administered form, so Padcev never reaches a retail shelf in any country. In Türkiye, the Ministry of Health anchors the reference price to the lowest ex-factory price found in a designated basket of EU member states, then converts it using the "pharmaceutical euro" (Dönemsel Avro Değeri), fixed at 65% of the prior year's average Central Bank euro rate rather than the live spot rate. That mechanism, published via the TİTCK price list and gazetted in the Resmî Gazete, is the principal reason Turkish list prices for complex ADCs like Padcev sit structurally below list prices in free-pricing markets.

Germany applies its AMNOG framework: a newly launched oncology ADC can carry a manufacturer-set free price for the first six months on the market, after which a negotiated price, agreed between the manufacturer and the GKV-Spitzenverband, applies — and crucially that negotiated figure is backdated to month seven rather than to the original launch date, so early adopters and payers absorb months of free pricing before the negotiated rate bites. The UK's NICE evaluates cost-effectiveness against a cost-per-QALY threshold that has just been raised from the long-standing £20,000–£30,000 band to £25,000–£35,000, announced 1 December 2025 and taking effect from April 2026 (see NICE); a wider threshold changes whether an ADC like Padcev clears the cost-effectiveness bar, but it does not itself set a price.

The United States has no equivalent statutory reference mechanism for a drug like Padcev: launch pricing is essentially free, set by the manufacturer, Astellas and Pfizer's co-development arrangement, and then negotiated privately and confidentially between the manufacturer, payers and pharmacy benefit managers. The RAND Corporation's 2022 international price comparison, published 1 February 2024, found gross US list prices averaged 278% of prices in 33 other high-income countries across all drugs, and 422% for brand-name originator products specifically — a structural, economy-wide gap rather than a figure specific to Padcev.

Because Padcev has no biosimilar or generic competitor anywhere and must be reconstituted from a lyophilised vial by a licensed hospital pharmacist immediately before infusion, it stays inside institutional tender procurement in every country rather than moving to retail: hospitals negotiate confidential discounts off the published list price through closed tenders, so the number you see published is rarely what any hospital actually pays. Every country comparison you encounter, including this one, should be read as a comparison of published list prices, not of net acquisition costs. For the underlying mechanics of why Türkiye's published prices sit where they do, see our explainer on why medicines cost less in Türkiye.

How is the price set in each country?

The table below compares pricing systems, not prices. Each country publishes — or does not publish — its own official list, and that published list is the only figure worth relying on. Follow the link in the last column and read the current entry yourself.

How can I obtain a medicine legally from a lower-price market?

There is a lawful route in most countries, and it starts in the same place everywhere: a valid prescription in your own name, issued by the physician treating you. What differs is the import permit. The procedures below are stated only where they could be verified at the national authority.

United Arab Emirates. MOHAP operates a permit to import medicines for personal use through its Electronic Drug Establishment service. The permit is free and is issued within 3 working days. You log in with a MOHAP account or UAE Pass.

Saudi Arabia. Applications run through the SFDA Controlled Drugs System at cds.sfda.gov.sa, under a guideline published on 14 August 2025. Read the current SFDA regulations page before you travel — the requirements are revised periodically.

Qatar. For non-controlled medicines there is no pre-approval: you may carry up to a 60-day supply through the Green Channel, in the original packaging, with a copy of the prescription and a signed, stamped letter from your doctor. For controlled medicines you need advance approval and must use the Red Channel; supporting documents must be no older than 6 months and in Arabic or English.

Kuwait and Azerbaijan. Confirm the current procedure directly with the national authority before shipping or travelling — Kuwait Ministry of Health and Azerbaijan Tariff Council. We do not publish a step list for these two countries because the procedure could not be verified at source.

1. United Arab Emirates — obtain a prescription in the applicant's own name, issued within the last 3 months.
2. Obtain a medical report from the treating facility, authenticated by the health authority and issued within the last year.
3. Prepare an Emirates ID or passport copy for the applicant.
4. Log in to the MOHAP service with a MOHAP account or UAE Pass and submit the personal-import application.
5. Keep the quantity within the limit: no more than a 1-month supply for controlled medicines, and no more than a 3-month supply for non-controlled medicines.
6. Wait for the decision — the service is free and normally issued within 3 working days.
7. Contact MOHAP on 800 111 11 or at import.export@mohap.gov.ae if the application stalls.

What is named patient supply?

Named patient supply is the international concept behind almost every lawful cross-border medicine route. The clearest codified example is the United Kingdom's MHRA Guidance Note 14, built on Regulation 167 of the Human Medicines Regulations 2012.

Four conditions define it: the order must be unsolicited; the product must be specified by the prescriber; the prescriber must be directly responsible for the patient; and there must be a genuine special clinical need that no authorised product meets.

The honesty point matters here: the European Court has held that "financial considerations cannot, in themselves" establish a special clinical need. A lower price in another country is not, by itself, a lawful basis for a named-patient import. The lawful bases are clinical.

Is the Padcev I'm being offered genuine?

No falsified batch of Padcev has been recorded in WHO's alert series to date. That absence of a public alert should not be read as a reason to relax verification: Padcev is a high-cost cytotoxic biologic administered only in hospital, and the same supply-chain risks that have affected other antibody–drug conjugates and checkpoint inhibitors apply in principle to any product diverted outside licensed distribution.

Because Padcev carries a cytotoxic MMAE payload, it must be handled, reconstituted and disposed of under hazardous-drug protocols by staff trained in cytotoxic handling inside a licensed hospital pharmacy — this is itself a practical barrier against diversion, since the product cannot realistically be prepared or administered outside that setting. Anyone offered a "ready to inject" Padcev vial outside a hospital pharmacy should treat that offer itself as the primary warning sign.

• Scan the vial carton's GS1 DataMatrix and confirm it decodes to AI 01 (GTIN), AI 21 (serial number), AI 17 (expiry) and AI 10 (batch) — a code that will not scan, or scans to the wrong product, is a hard stop.
• If the vial is sourced in Türkiye, confirm its karekod is notified to the national İlaç Takip Sistemi (İTS) track-and-trace system at its.saglik.gov.tr before it leaves the pharmacy.
• Ask for a continuous 2–8°C temperature log covering the actual shipment you are receiving, not a generic cold-chain certificate — Padcev must never be frozen or shaken.
• Confirm reconstitution happens only inside a licensed hospital pharmacy under cytotoxic-handling protocols; a pre-reconstituted or "ready to use" Padcev offered outside that setting is not a legitimate supply.
• Cross-check the batch and lot number against our WHO falsified medicine alerts tracker before administration — no falsified Padcev batch has been logged there to date, but the check itself is the safeguard.
• Be suspicious of any website or broker offering a public "manufacturer batch checker" for Padcev: no such consumer-facing tool is operated by Astellas or Pfizer.
• Review the full verification workflow in our guide to checking that a medicine is genuine.

Frequently asked questions

Sources

• Resmî Gazete — Beşeri Tıbbi Ürünlerin Fiyatlandırılmasına Dair Karar No. 11031 — retrieved: 2026-07-28
• TİTCK — published medicine price list — retrieved: 2026-07-28
• MOHAP (UAE) — import medicine for personal use — retrieved: 2026-07-28
• SFDA (Saudi Arabia) — regulations — retrieved: 2026-07-28
• SFDA Controlled Drugs System — retrieved: 2026-07-28
• Qatar MOPH — drug prices — retrieved: 2026-07-28
• Kuwait Ministry of Health — retrieved: 2026-07-28
• Azerbaijan Tariff Council (Tarif Şurası) — retrieved: 2026-07-28
• NICE (United Kingdom) — retrieved: 2026-07-28
• G-BA (Germany) — AMNOG benefit assessment — retrieved: 2026-07-28
• RAND — International prescription drug price comparisons (published 1 Feb 2024) — retrieved: 2026-07-28
• Frontiers in Pharmacology — European hospital price transparency study (9 Mar 2026) — retrieved: 2026-07-28
• MHRA Guidance Note 14 — supply of unlicensed medicinal products — retrieved: 2026-07-28

Country availability pages for this medicine

Related pages

Antibody–drug conjugates

Related high-cost medicines